Redwood Pharma to present at the BioStock Life Science Summit in Lund and Stockholm on 8-9 June 2022
Redwood Pharma will participate in the BioStock Life Science Summit in Lund and in Stockholm. CEO Martin Vidaeus will update the market about, among several topics, the start of the RP501 clinical trial – the company’s first-line medical technology therapy for dry eye – and the company’s plans for the future.
BioStock Life Science Spring Summit offers an important platform for Nordic innovation companies, which get the chance to pitch their projects to both Swedish and international investors, industry colleagues and potential partners. The presentation will be held in English.
The event program and registration can be found on the event’s website, where there will also be a link to stream the presentation.
For further information
Martin Vidaeus – CEO, Phone: +46 70-232 29 29
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs through novel approaches. In providing commercial partners and their customers with effective medical solutions, the Company is currently developing treatments for dry eye disease in various target patient populations. The RP101 program targets moderate-to-severe dry eye disease in post-menopausal women by delivering a low-dose estrogen therapy to the front of the eye. The RP501 program aims to treat milder forms of dry eye in a broader patient population including both men and women of all ages. For other potential drug substances and therapeutic areas, the Company can employ the IntelliGel drug delivery platform that enhances patient convenience by controlling dosing and potentially reducing the number of instillations per day and subsequent side-effects. Redwood Pharma leverages its strengths in early clinical development and aims to generate revenues through, among others, licensing agreements with companies that have capabilities to manufacture and sell medical products worldwide.
Redwood Pharma AB (publ) is listed on the Nasdaq First North Growth stock market (Ticker: REDW.ST, ISIN: SE008294789).
For more information visit: www.redwoodpharma.com